

Jan 13, 2015

Announcement of Signing of License Agreement regarding OP0595, a Beta-Lactamase Inhibitor

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President: Daikichiro Kobayashi, hereinafter "Meiji") announced today that F. Hoffmann-La Roche Ltd. (Head Office: Basel, Switzerland. CEO: Severin Schwan, hereinafter "Roche"), Fedora Pharmaceuticals Inc. (Head Office: Edmonton, Canada. CEO: Christopher G. Micetich, hereinafter "Fedora") and Meiji have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor.

Under the agreement, Roche exclusively obtains worldwide rights and license, excluding Japan, to develop, manufacture and commercialize OP0595. In consideration of the license granted to Roche, Meiji and Fedora will receive an initial upfront payment and following development, regulatory and sales event milestones payments, as well as tiered royalties.

OP0595 has been discovered through Meiji's proprietary technology for infectious disease and is currently under Phase I conducted by Meiji. OP0595, via its unique mode of action, restores the efficacy of beta-lactam antibiotics against infections caused by beta-lactamase producing, antibiotic-resistant bacteria. OP0595 is used in combination with beta-lactam antibiotics that will promise a significant advancement in the battle against drug-resistant bacterial infection increasing in the world.

About Roche

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics. For more information, please visit www.roche.com

About Fedora

Fedora is a private biotechnology company founded in 2012 and is headquartered in Edmonton, Alberta, Canada. For more information on the company, please visit www.fedorapharma.com.